February 2020

– Study Results Expected Q4 2020 Feb 19, 2020, 07:30 ET CRANBURY, N.J., Feb. 19, 2020 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, today announced that it has enrolled the first patient …

Palatin Technologies, Inc. Announces First Patient Enrolled in Dry Eye Disease Phase 2 Clinical Trial with PL9643 Read More »

— Dry Eye Disease Phase 2 Study to Commence Q1 2020 — Data Q4 2020 — Approximately $92 Million in Cash and Cash Equivalents at December 31, 2019 — AMAG Announced Plans to Divest Vyleesi® for Premenopausal Women with Hypoactive Sexual Desire Disorder (HSDD) — Teleconference and Webcast to be held on February 11, 2020 …

Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2020 Financial Results and Recent Business Highlights Read More »

Feb 06, 2020, 07:30 ET CRANBURY, N.J., Feb. 6, 2020 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) will announce its second quarter fiscal year 2020 operating results on Tuesday, February 11, 2020 before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its …

Palatin Technologies, Inc. to Report Second Quarter Fiscal Year 2020 Results; Teleconference and Webcast to be held on February 11, 2020 Read More »